Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine

xlomafota13 shared this article with you from Inoreader Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine Via radioactive iodine Endocr Connect. 2021 Sep 1:EC-21-0187.R2. doi: 10.1530/EC-21-0187. Online ahead of print. ABSTRACT Treatment with radioactive iodine (RAI) in women with differentiated thyroid cancer is associated with decreased serum concentrations of anti-Müllerian hormone (AMH); however, other markers have not been investigated. Therefore, this study aimed to evaluate the effect of RAI on antral follicle count (AFC) and the serum concentration of inhibin B, follicle-stimulating hormone (FSH), a nd AMH in women with papillary thyroid cancer (PTC) treated with RAI. We examined 25 women at a median age of 33 years treated with a single dose of RAI. We divided the participants into women over (n = 11) and under 35 years of age (n = 14). Serum concentrations of inhibin B, FSH, AMH, and AFC were assessed at baseline and one year after RAI treatment. We found decreased AFC (p = 0.03), serum levels of AMH (p < 0.01), inhibin B (p = 0.03), but not FSH (p = 0.23), one year after RAI treatment in comparison to baseline in the whole group. When we compared serum levels of AMH in younger vs. older women separately, we observed a significant reduction of this hormone's serum level after RAI treatment in both groups (p < 0.01; p = 0.04, respectively). We concluded that RAI treatment significantly impacts the functional ovarian reserve in premenopausal women with PTC. PMID:34524978 | DOI:10.1530/EC-21-0187 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.